| First Author | Sørensen IK | Year | 1997 |
| Journal | Carcinogenesis | Volume | 18 |
| Issue | 4 | Pages | 777-81 |
| PubMed ID | 9111214 | Mgi Jnum | J:39818 |
| Mgi Id | MGI:87167 | Doi | 10.1093/carcin/18.4.777 |
| Citation | Sorensen IK, et al. (1997) Short-term carcinogenicity testing of a potent murine intestinal mutagen, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP), in Apc1638N transgenic mice. Carcinogenesis 18(4):777-81 |
| abstractText | Transgenic Apc1638N mice, heterozygous for a targeted frameshift mutation at codon 1638 of the endogenous adenomatous polyposis coli (APC) gene, are predisposed to develop multiple adenomas and adenocarcinomas along the intestinal tract and to a number of extra-intestinal lesions including, among others, mammary tumors. We have studied these mice in a short-term carcinogenicity test with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP), a potent murine small intestinal mutagen and lymphomagen. Upon dietary administration of 0.03% PhIP in a short-term (6 months) study, a significantly increased number of small intestinal tumors as well as an increased number of aberrant crypt foci (ACF) were observed in male Apc+/Apc1638N mice compared with untreated transgenic mice. No differences in intestinal and mammary tumor multiplicity were observed between treated and control Apc+/Apc1638N females. |
